Murine rheumatoid arthritis models are often used to investigate the potential therapeutic effects of candidate drugs. The present study has been conducted in order to investigate the therapeutic efficacy of ascidian tunicate extracts in a collagen-induced arthritis DBA1/J mice model. Four types of formulas, ascidian tunicate extracts (ATE), crude ascidian tunicate glycans (ATEC), ascidian tunicate extracts with licorice extracts (ATEL), and crude ascidian tunicate glycans with licorice extracts (ATECL) were orally administered into DBA/1J mice for 3 weeks and paw edema and thickness were evaluated. Changes in inflammatory proteins and cytokines levels were monitored in hind leg tissues by Western blot and quantitative PCR analysis. The oral administration of ascidian tunicate extracts alleviated paw edema and improved the histological hind leg cartilage status. The extracts also reduced the matrix metalloproteinase-9 (MMP-9) protein and prostaglandin E synthase (PGES) levels. In addition, the extracts-treated groups showed increased interleukin-10 (IL-10) levels compared with the non-treated group. These findings suggest that orally administered ascidian tunicate extracts might have potential therapeutic effects for the treatment of rheumatoid arthritis.
Rheumatoid arthritis is a chronic inflammatory disease associated with joint swelling and extracellular matrix degeneration induced by pro-inflammatory cytokines [1] . Matrix destruction is caused by various proteolytic enzymes and inflammatory cells [2] . Metalloproteinases (MMPs) are involved in the pathogenesis of human arthritis and gelatinase B (MMP-9) is particularly known to be closely associated with extracellular matrix invasion [3] [4] . In rheumatoid arthritis, MMPs and prostaglandin E2 are produced by fibroblast-like synoviocytes, and further enhance inflammation [5] . Collagen-induced arthritis (CIA) in mice is an autoimmune model of rheumatoid arthritis induced by complete Freund's adjuvant and type II collagen. CIA is a widely used model of inflammatory polyarthritis and is similar to human rheumatoid arthritis in terms of clinical symptoms [6] .
Various types of medications have been used for the treatment of rheumatoid arthritis, including non-steroidal anti-inflammatory drugs (NSAID), tumor necrosis factor (TNF) antagonists and disease-modifying anti-rheumatic drugs (DMARDs). However, these drugs are known to induce side effects frequently. NSAIDs, such as paracetamol, mainly cause adverse effects in the gastrointestinal tract and the kidney [7] . TNF-α blockers may cause sarcoidosis, morphea and pleuropericarditis [8] [9] [10] . Leflunomide, one of the DMARDs, may cause either peripheral neuropathy [11] or acute interstitial pneumonia [12] . In addition, methotrexate may induce nephrotoxicity and tubular apoptosis through the activation of poly (ADP ribose) polymerase (PARP) [13] . The worldwide trend is, therefore to search for new therapeutics from natural products without the side effects of the existing medications [14] [15] [16] .
In our previous study, chondroitin sulfate (CS) extracted from an ascidian tunicate displayed anti-inflammatory properties in the mouse skin through inhibition of NK-κB activation [17] , which was consistent with data obtained with CS extracted from Styela clava tunicate on Akt/NF-κB signaling [18] . CS is a glycosaminoglycan (GAG) and belongs to the symptomatic slowacting drugs for the treatment of the osteoarthritis (SYSADOA) family [19, 20] . CS inhibits NF-κB nuclear translocation [21] and suppresses proinflammatory gene expression [22] . In this study, we focused on the potential therapeutic effects of ascidian tunicate extracts for the treatment of arthritis.
In order to investigate the therapeutic effects of ascidian tunicate extracts, we set 7 experimental groups; Naïve, Induced, ascidian tunicate extracts-treated groups (ATE, ATEC, ATECL and ATEL) and one leflunomide-treated group (Table 1) . The leflunomidetreated group was set as a positive control since leflunomide is a well-known effective drug for the treatment of rheumatoid arthritis [23] and has also been shown to have anti-inflammatory properties in an animal model [24] . The mice were first sensitized with bovine type II collagen and adjuvant (Day 0, 21), and then treated with extracts of ascidian tunicate and leflunomide for 3 weeks (Days 28-48) (Figure 1 ).
To validate the therapeutic effects of ascidian tunicate extracts in our murine arthritis model, we first measured paw edema and thickness. The induction of arthritis has been shown to be associated with increased paw edema [25] and thickness [26] , and previous studies also showed a reduction in paw volume [27] and thickness [28] is a good marker of arthritis alleviation. We, therefore, measured and compared paw edema and the thickness using a plethysmometer and calipers 28 and 70 days after rheumatoid arthritis induction. The induced group showed remarkably increased paw edema and thickness values while all the treated groups (ATE, ATEC, ATECL, ATEL and Leflunomide) showed significantly decreased values compared with the induced group (Figure 2A and B). Thus, our data suggest that ascidian tunicate extracts may have therapeutic effects for the treatment of arthritis. To confirm the therapeutic effects of ascidian tunicate extracts, we also evaluated their effects on several markers of the immune system, such as matrix metalloproteinase-9 (MMP-9) protein, prostaglandin E synthase (PGES) and interleukin-10 (IL-10) levels. MMP-9 is associated with joint degeneration and inflammatory arthritis progression [29] and the expression of MMP-9 is increased in rheumatoid arthritis synovial tissues [30] and synovial effusions [31] . Moreover, previous data demonstrated that the efficiency of a drug to lower MMP-9 expression is dose-dependently correlated with its preventive effects against arthritis [32, 33] . In this study, we analyzed MMP-9 expression using Western blots, and the intensity of the bands was measured by densitometry ( Figure 3A , B). All treatments displayed a tendency to decrease MMP-9 expression levels, but only ATECL, ATEL and Leflunomide significantly decreased MMP-9 expression compared with the control group (induced). Nevertheless, our results suggest that the therapeutic effects of ascidian tunicate extracts are associated with decreased MMP-9 expression. PGES catalyzes the formation of prostaglandin E2 (PGE2) from prostaglandin H2 (PGH2) and PGE2 is a key inflammatory mediator. PGES is highly expressed in the synovial lining cells of rheumatoid arthritis patients [34] . Moreover, PGES is a recognized target of rheumatic diseases and is associated with symptoms of chronic inflammation and pain [35, 36] . Our results showed that all treated groups (ATE, ATEC, ATECL, ATEL and Leflunomide) displayed significantly decreased PGE2 mRNA levels compared with the induced group ( Figure 3C ). Moreover, interleukin-10 (IL-10) acts as an anti-inflammatory cytokine in rheumatoid arthritis [37] and reduced IL-10 levels have been associated with exacerbated inflammatory conditions in collagen-induced arthritis [38] . We showed that ATEC, ATECL, ATEL and Leflunomide significantly increased IL-10 levels compared with the induced group ( Figure 3D ). It has been shown that increased IL-10 levels could strongly prevent cell proliferation through the inhibition of the antigen-presenting capacity of immune cells [39] and are associated with a reduction of inflammation in arthritis conditions [40] . Taken together, our data suggest that ascidian tunicate extracts have anti-inflammatory properties for the treatment of inflammation-associated arthritis.
In order to further investigate the therapeutic effects of the extracts in the joint, we examined slides of hind leg joint cartilage using hematoxylin and eosin (H&E) staining. Our histopathological experiments showed that, although the induced group presented severe cartilage destruction and erosion, the treated groups displayed mildly affected cartilage (Figure 4 ). In order to investigate the toxicity of the different ascidian tunicate extracts, alanine transaminase (ALT), also called glutamic pyruvic transaminase (GPT), levels were analyzed. Although the ATEL group showed significantly increased ALT (GPT) levels compared with the Induced group, all ascidian tunicate extract-administered groups displayed lower levels than the Leflunomide group. Interestingly, the ATEC group showed similar levels as those of the induced group ( Figure 5 ).
Our data demonstrate that ascidian tunicate extracts have antiinflammatory properties through the inhibition of inflammatory proteins and cytokines, such as MMP-9 and PGES, and through an increase of anti-inflammatory IL-10 levels. Moreover, ascidian tunicate extract treatments also improved cartilage status compared with the Induced group. More specifically, extracts containing licorice (ATECL, ATEL) induced the strongest therapeutic effects on paw edema and PGES expression. Interestingly, licorice has also been shown in previous studies to inhibit inflammation, including arthritis [41, 42] . Therefore, ascidian tunicate extracts and licorice could act synergistically for the treatment of arthritis. Moreover, all treated groups showed less toxic effects than the Leflunomide group. In conclusion, our study strongly suggests that ascidian tunicate extracts have anti-inflammatory properties and could present novel and biocompatible natural therapeutics for the treatment of inflammation associated with arthritis. Preparation of ascidian tunicate extracts and mixture: Ascidian (Halocynthia roretzi) tunicates were collected from Tongyeong, Korea. In order to extract the lipids and carotenoids, the animals were soaked in 3 volumes of acetone (w/v) that were replaced 3 times with fresh solvent. The tunicates were washed with distilled water several times in order to remove the acetone, and then airdried and cut into small pieces. For the extraction of sulfated glycans, 1 Kg was pressure-extracted in 5 volumes (w/v) of deionized water at 121°C for 3 h. The water-soluble fraction was centrifuged at 8,000 rpm for 20 min. The supernatants were pooled and concentrated using a vacuum evaporator until Brix 2, lyophilized and labeled ATE (ascidian tunicate extracts). Two volumes of un-lyophilized ATE were mixed with one volume of licorice (Glycyrrhiza uralensis Fisch.) extracts (Brix 2) and 500 ppm of vitamin C. This mixture was then lyophilized and named ATEL (ascidian tunicate extracts with licorice extracts). In order to obtain further purified sulfated glycans from the ascidian tunicates, we used the method of Albano et al. [43] , with slight modifications. In brief, the dried tunicates (~ 1 g) were suspended in 20 mL of 0.2 M sodium phosphate buffer (pH 5.7) containing 5 mM EDTA, 5 mM cysteine, and 10 mg of papain (Sigma P4762), and then incubated at 60°C for 24 h. After incubation, the enzymes were inactivated at 80°C for 20 min. After filtration, HCl (final concentration 2.0 N) was added to precipitate the proteins. The mixture was then neutralized with 2.0 N NaOH until pH 6.5 and centrifuged at 8,000 rpm for 20 min. The supernatant was dialyzed with deionized water to remove the salts, and then concentrated with a vacuum evaporator until Brix 9-10. The concentrate was mixed with 3 volumes of 95% ethanol and incubated at 4°C overnight. Precipitates of crude sulfated glycans were obtained after centrifugation at 8,000 rpm for 20 min. For further purification, the precipitates were collected and dissolved in 5 volumes of deionized water and filtered with TFF Millipore™ (EMD Millipore Co., Billerica, MA, USA) using a Pellicon XL cassette with a 5 kD molecular cut off. The filtrate was then lyophilized and labeled ATEC (crude ascidian tunicate glycans extracts).
Experimental

Reagents and materials:
To obtain ascidian tunicate sulfated glycans extracts enriched with licorice (ATECL or crude ascidian tunicate glycans extracts with licorice extracts), 10 g of ATEC were dissolved in 300 mL of deionized water, mixed with 100 mL of licorice (Brix 2) and then lyophilized. All the lyophilized samples were stored at -20°C for further analysis.
Animals, arthritis induction and treatments:
Six-week-old male DBA/1J mice were purchased from Joongang Laboratory Animal Incorporation (Seoul, Korea). All animals were maintained in the animal facility with the temperature and relative humidity maintained at 23±2°C and 50±10%, respectively, as well as a 12 h light/dark cycle. Three mice were used in the Naïve group. We used the collagen-induced arthritis method described previously in mice [44] . Mice, except the Naïve control group, were sensitized by bovine type II collagen on days 0 and 21. Type II collagen (2 mg/mL) was prepared in 0.05 M acetic acid and emulsified with an equal volume of CFA. The resulting solution was injected intradermally at the base of the tail (day 0) and 3 weeks later, the mice were administered IFA emulsified bovine type II collagen (day 21). One week later (day 28), 36 arthritis-induced mice were randomly distributed into 6 groups (6 mice per group), as shown in Table 1 : Induced, ATE, ATEC, ATECL, ATEL and Leflunomide. Ascidian tunicate (100 μL of 100 mg/kg ATE, ATEC, ATECL or 850 Natural Product Communications Vol. 9 (6) 2014
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ATEL) was orally administered to each group for 3 weeks, 5 days per week (day 28 to day 48). Leflunomide (100 μL of a 10 mg/kg solution) was also orally administered to the Leflunomide group for 3 weeks, 5 days per week (day 28 to day 48). Distilled water (100 μL) was administered to the Naïve and Induced groups. At the end of the experiment (day 70), the animals were sacrificed and the blood and hind legs were collected for further analysis (Figure 1 ). All the methods used in this study were approved by the Animal Care and Use Committee at Seoul National University (SNU-120628-2).
Hind paw volume and paw thickness measurement: Hind paw volume was measured on days 28 and 70 using an electronic water plethysmometer (UGO BASILE, Comerio-Varese, Italy). Hind paw volume increases were expressed as the percentage of volume increase on day 70 compared with day 28 using the following equation: (day 70 volume -day 28 volume) × 100 / day 28 volume. We measured paw thickness on days 28 and 70 using a digital caliper. Paw thickness was also expressed as the percentage of thickness increase on day 70 compared with day 28 using the following equation: (day 70 thickness -day 28 thickness) × 100 / day 28 thickness [45] .
Western blot analysis:
Hind leg joints were homogenized using 500 μL of a 2.5 X Passive Lysis Buffer (Promega, Madison, WI, USA) containing a Xpert Protease Inhibitor Cocktail solution (GenDEPOT, CA, USA) for protein analysis. The samples were centrifuged at 13,200 rpm for 30 min, and the supernatants were collected. Fifty µg of proteins were loaded on a SDS-PAGE gel. The separated proteins were transferred to nitrocellulose membranes and blocked for 30 min in 5% skim milk. The membranes were incubated O/N with the primary antibody (1:1000) in 5% skim milk at 4°C. After washing with a TTBS (Tris-Buffered Saline + Tween 20) solution for 10 min, the membranes were incubated with the horse-radish peroxidase-conjugated secondary antibody (1:2500, Invitrogen, Carlsbad, CA, USA) for 3 h at room temperature. After washing with TTBS solution 3 times for 30 min, bands were detected using a luminescent image analyzer {Ez-Capture MG (ATTO, Tokyo, Japan)}. The analysis of the Western blot bands was performed using Multi Gauge version 2.02 software (Fujifilm, Tokyo, Japan).
Real-time qPCR (quantitative polymerase chain reaction):
Total RNAs were isolated using the QuickGene RNA kit (Fujifilm's Life Science System, Tokyo, Japan) and subjected to the SuPrimeScript RT Premix (GeNet Bio, Daejeon, Korea) from frozen hind leg joints. The reverse transcription reaction was performed using the following conditions: 25°C for 10 min, 30°C for 30 min, and 85°C for 5 min. Real-time qPCRs were conducted with the CFX96T Real-time System (Bio-Rad, Richmond, CA, USA) and each cDNA was amplified with specific primers and Prime Q-Mastermix (GeNet Bio, Daejeon, Korea) under the following cycling conditions: initial denaturation at 94°C for 10 min, denaturation at 94°C for 30 sec, annealing at 59°C for 30 sec and extension at 72°C for 45 sec, for 40 cycles with a final extension at 72°C for 5 min. The sequences of the primers used for the qPCR were as follows: mouse PGES, forward (5'-ACAGGAGTGACCCAGATG-3') and reverse (5'-GAAGCCGAGGAAGAGGAA-3'); mouse IL-10, forward (5'-GCCCTTTGCTATGGTGTC-3') and reverse (5'-TCTCCCTGGTTTCTCTTCC-3'); mouse β-actin, forward (5′-TTTCCAGCCTTCCTTCTTGGGTATG-3′) and reverse (5′-CACTGTGTTGGCATAGAGGTCTTTAC-3′). The real-time PCR products were analyzed with the Bio-Rad CFX Manager Version 2.1 Software (Bio-Rad, Richmond, CA, USA).
Tissue histopathology: Hind legs were collected and fixed in 10% neutral-buffered formalin. The next day, the tissues were decalcified in a 5% formic acid-formalin solution. One week later, the tissues were embedded in paraffin, sectioned with a thickness of 5 μm and stained with hematoxylin and eosin (Sigma-Aldrich, St Louis, MO, USA) for H&E staining. Sectioned tissues were mounted using cover slips and Permount (Fisher Scientific, Fair Lawn, NJ, USA). Tissue slides were examined using the light microscope Axioplan 2 (Karl-Zeiss, Frankfurt, Germany).
Detection of ALT (GPT) levels in serum:
ALT (GPT) levels in serum were estimated by commercially available GPT detection kit (Asan Pharmaceutical Co., Seoul, Korea) according to the manufacturer's instructions.
Statistical analysis: Statistical significances were analyzed using Microcal Origin student's t-test two populations (Microcal Software, Northampton, MA, USA) and the significance was set at *P<0.05, **P<0.01 and ***P<0.001 compared with the corresponding control values.
